文献速递自身免疫性与大疱性皮肤病

利妥昔单抗与天疱疮患者长期心血管及代谢结局风险的关联

Association of Rituximab With Risk of Long-term Cardiovascular and Metabolic Outcomes in Patients With Pemphigus.
PubMed 文献 · JAMA Dermatol · 2023-01-01

这项全球回顾性队列研究纳入天疱疮患者,比较利妥昔单抗与硫唑嘌呤/吗替麦考酚酯(MMF)对长期心血管代谢结局及全因死亡的影响。结果显示利妥昔单抗组心肌梗死、卒中、外周血管病、高血压、高脂血症、2型糖尿病、肥胖和骨质疏松风险均较低,全因死亡无显著差异。作者认为利妥昔单抗可能对长期心血管代谢结局有保护作用。

要点

  • 利妥昔单抗组心肌梗死风险低于硫唑嘌呤/MMF组(RR 0.45,95%CI 0.24-0.86,P=.01)。
  • 利妥昔单抗组卒中、外周血管病、高血压、高脂血症、2型糖尿病、肥胖和骨质疏松风险均较低。
  • 两组全因死亡风险无显著差异(HR 0.94,95%CI 0.62-1.43,log-rank P=.77)。

核心结论

  • 这项队列研究结果提示,与常规免疫抑制剂相比,利妥昔单抗与长期心血管和代谢结局的保护作用相关。
  • 作者认为,对于已有心血管和代谢危险因素的个体,可能尤其优先选择利妥昔单抗。

研究设计与样本

  • 全球性基于人群的回顾性队列研究,比较接受利妥昔单抗治疗的天疱疮患者与接受硫唑嘌呤或吗替麦考酚酯(MMF)治疗的患者。
  • 共纳入961例接受利妥昔单抗治疗的患者和961例接受硫唑嘌呤或MMF治疗的患者,采用倾向性评分匹配以优化可比性。
  • 患者来自TriNetX平台的全球协作网络。

主要发现

  • 1602例参与者中,女性855例(53.4%),男性747例(46.6%);利妥昔单抗组平均(SD)年龄为54.8(16.6)岁,硫唑嘌呤/MMF组为54.4(18.2)岁。
  • 与硫唑嘌呤/MMF组相比,利妥昔单抗组心肌梗死风险较低(RR 0.45,95%CI 0.24-0.86,P=.01)。
  • 与硫唑嘌呤/MMF组相比,利妥昔单抗组卒中风险较低(RR 0.42,95%CI 0.26-0.69,P<.001)。
  • 与硫唑嘌呤/MMF组相比,利妥昔单抗组外周血管病风险较低(RR 0.47,95%CI 0.28-0.79,P=.003)。
  • 与硫唑嘌呤/MMF组相比,利妥昔单抗组高血压风险较低(RR 0.48,95%CI 0.38-0.63,P<.001)。

关键数值与推荐

  • 与硫唑嘌呤/MMF组相比,利妥昔单抗组高脂血症风险较低(RR 0.45,95%CI 0.32-0.64,P<.001)。
  • 与硫唑嘌呤/MMF组相比,利妥昔单抗组2型糖尿病风险较低(RR 0.63,95%CI 0.51-0.77,P<.001)。
  • 与硫唑嘌呤/MMF组相比,利妥昔单抗组肥胖风险较低(RR 0.49,95%CI 0.34-0.72,P<.001)。
  • 与硫唑嘌呤/MMF组相比,利妥昔单抗组骨质疏松风险较低(RR 0.46,95%CI 0.30-0.71,P<.001)。
  • 两组全因死亡率相当(HR 0.94,95%CI 0.62-1.43,log-rank P=.77)。

临床怎么用

  • 作者认为,利妥昔单抗可能尤其优先用于已有心血管和代谢危险因素的天疱疮个体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The association of different therapeutic approaches with long-term cardiovascular and metabolic outcomes in patients with pemphigus remains to be precisely evaluated. OBJECTIVE: To assess the risk of long-term cardiovascular and metabolic outcomes and all-cause mortality in patients with pemphigus managed by rituximab compared with those receiving treatment with first-line corticosteroid-sparing agents (azathioprine and mycophenolate mofetil [MMF]). DESIGN, SETTING, AND PARTICIPANTS: A global population-based retrospective cohort study compared 961 patients with pemphigus that was managed with rituximab with those treated with azathioprine or MMF (n = 961) regarding the risk of several cardiovascular and metabolic outcomes. Propensity score matching was performed to optimize comparability. Patients were enrolled from the Global Collaborative Network of TriNetX platform. MAIN OUTCOMES AND MEASURES: Risk of myocardial infarction, stroke, peripheral vascular disease, pulmonary embolism, hypertension, hyperlipidemia, type 2 diabetes, obesity, osteoporosis, and avascular bone necrosis. RESULTS: Of 1602 participants, 855 (53.4%) were women and 747 (46.6%) were men; the mean (SD) age was 54.8 (16.6) years for those treated with rituximab and 54.4 (18.2) years for those treated with azathioprine or MMF. Compared with those treated by azathioprine/MMF, patients treated with rituximab experienced a lower risk of myocardial infarction (relative risk [RR], 0.45; 95% CI, 0.24-0.86; P = .01), stroke (RR, 0.42; 95% CI, 0.26-0.69; P < .001), peripheral vascular disease (RR, 0.47; 95% CI, 0.28-0.79; P = .003), hypertension (RR, 0.48; 95% CI, 0.38-0.63; P < .001), hyperlipidemia (RR, 0.45; 95% CI, 0.32-0.64; P < .001), type 2 diabetes (RR, 0.63; 95% CI, 0.51-0.77; P < .001), obesity (RR, 0.49; 95% CI, 0.34-0.72; P < .001), and osteoporosis (RR, 0.46; 95% CI, 0.30-0.71; P < .001). The all-cause mortality was comparable between patients in both groups (hazard ratio, 0.94; 95% CI, 0.62-1.43; log-rank P = .77). CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that rituximab was associated with protection against long-term cardiovascular and metabolic outcomes compared with conventional immunosuppressants. This agent might be particularly preferred in individuals with preexisting cardiovascular and metabolic risk factors.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Kridin K, Mruwat N, Ludwig RJ, et al. Association of Rituximab With Risk of Long-term Cardiovascular and Metabolic Outcomes in Patients With Pemphigus. JAMA Dermatol. 2023. PMID: 36449276. doi:10.1001/jamadermatol.2022.5182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。